In the last trading session, 1.28 million shares of the Immunic Inc (NASDAQ:IMUX) were traded, and its beta was 1.85. Most recently the company’s share price was $1.31, and it changed around -$0.03 or -2.24% from the last close, which brings the market valuation of the company to $118.00M. IMUX currently trades at a discount to its 52-week high of $2.11, offering almost -61.07% off that amount. The share price’s 52-week low was $0.95, which indicates that the current value has risen by an impressive 27.48% since then. We note from Immunic Inc’s average daily trading volume that its 10-day average is 1.79 million shares, with the 3-month average coming to 599.39K.

Immunic Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended IMUX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Immunic Inc is expected to report earnings per share of -0.22 for the current quarter.

Immunic Inc (NASDAQ:IMUX) trade information

Instantly IMUX has showed a red trend with a performance of -2.24% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4800 on recent trading dayincreased the stock’s daily price by 11.49%. The company’s shares are currently down -12.67% year-to-date, but still down -6.43% over the last five days. On the other hand, Immunic Inc (NASDAQ:IMUX) is -20.61% down in the 30-day period. We can see from the shorts that 3.47 million shares have been sold at a short interest cover period of 5.76 day(s).

The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 73.8% from its current value. Analyst projections state that IMUX is forecast to be at a low of $5 and a high of $5.

Immunic Inc (IMUX) estimates and forecasts

Immunic Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 3.97 percent over the past six months and at a 54.50% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 56.90% in revenue this quarter, and will report an increase of 56.30% in the next quarter.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 10k in revenue for the current quarter. 4 analysts expect Immunic Inc to make 10k in revenue for the current ending quarter.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.12%. Immunic Inc earnings are expected to increase by 56.87% in 2024, but the outlook is positive 15.50% per year for the next five years.

IMUX Dividends

Immunic Inc’s next quarterly earnings report is expected to be released in November.

Immunic Inc (NASDAQ:IMUX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 3.34% of Immunic Inc shares, and 62.50% of them are in the hands of institutional investors. The stock currently has a share float of 64.66%. Immunic Inc stock is held by 70.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 9.15% of the shares, which is about 8.9 million shares worth $9.88 million.

AVIDITY PARTNERS MANAGEMENT LP, with 9.15% or 8.9 million shares worth $9.88 million as of 2024-06-30, holds the second largest percentage of outstanding shares.